Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies

7Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

Targeting the RAS pathway remains the holy grail of precision oncology. In the case of pancreatic ductal adenocarcinomas (PDAC), 90–92% harbor mutations in the oncogene KRAS, triggering canonical MAPK signaling. The smooth structure of the altered KRAS protein without a binding pocket and its affinity for GTP have, in the past, hampered drug development. The emergence of KRASG12C covalent inhibitors has provided renewed enthusiasm for targeting KRAS. The numerous pathways implicated in RAS activation do, however, lead to the development of early resistance. In addition, the dense stromal niche and immunosuppressive microenvironment dictated by oncogenic KRAS can influence treatment responses, highlighting the need for a combination-based approach. Given that mutations in KRAS occur early in PDAC tumorigenesis, an understanding of its pleiotropic effects is key to progress in this disease. Herein, we review current perspectives on targeting KRAS with a focus on PDAC.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Linehan, A., O’Reilly, M., McDermott, R., & O’Kane, G. M. (2024). Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies. Frontiers in Medicine. Frontiers Media SA. https://doi.org/10.3389/fmed.2024.1369136

Readers' Seniority

Tooltip

Professor / Associate Prof. 2

67%

PhD / Post grad / Masters / Doc 1

33%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 2

50%

Materials Science 1

25%

Social Sciences 1

25%

Article Metrics

Tooltip
Mentions
News Mentions: 2

Save time finding and organizing research with Mendeley

Sign up for free